Future Directions for Cost-effectiveness Analyses in Health and Medicine

被引:60
|
作者
Neumann, Peter J. [1 ]
Kim, David D. [1 ]
Trikalinos, Thomas A. [2 ]
Sculpher, Mark J. [3 ]
Salomon, Joshua A. [4 ]
Prosser, Lisa A. [5 ,6 ]
Owens, Douglas K. [4 ,7 ]
Meltzer, David O. [8 ,9 ,10 ]
Kuntz, Karen M. [11 ]
Krahn, Murray [12 ]
Feeny, David [13 ]
Basu, Anirban [14 ]
Russell, Louise B. [15 ,16 ]
Siegel, Joanna E. [17 ]
Ganiats, Theodore G. [18 ]
Sanders, Gillian D. [19 ]
机构
[1] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Evaluat Value & Risk Hlth CEVR, Boston, MA USA
[2] Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice, Providence, RI 02912 USA
[3] Univ York, Ctr Hlth Econ, York, N Yorkshire, England
[4] Stanford Univ, Ctr Hlth Policy, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA
[5] Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Child Hlth Evaluat & Res Unit, Ann Arbor, MI USA
[6] Univ Michigan, Sch Publ Hlth, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA
[7] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA
[8] Univ Chicago, Harris Sch Publ Policy Studies, Dept Med, Chicago, IL 60637 USA
[9] Univ Chicago, Harris Sch Publ Policy Studies, Dept Econ, Chicago, IL 60637 USA
[10] Univ Chicago, Ctr Hlth & Social Sci, Chicago, IL 60637 USA
[11] Univ Minnesota, Sch Publ Hlth, Div Hlth Policy & Management, Minneapolis, MN USA
[12] Univ Toronto, Toronto Gen Hosp Res Inst TGRI, Toronto Hlth Econ & Technol Assessment THETA Coll, Toronto, ON, Canada
[13] McMaster Univ, Dept Econ, Hamilton, ON, Canada
[14] Univ Washington, Dept Hlth Serv & Econ, Comparat Hlth Outcomes Policy & Econ CHOICE Inst, Dept Pharm, Seattle, WA 98195 USA
[15] Univ Penn, Perelman Sch Med, Ctr Hlth Incent & Behav Econ, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA
[16] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA
[17] Patient Ctr Outcomes Res Inst, Washington, DC USA
[18] Univ Calif San Diego, Dept Family Med & Publ Hlth, La Jolla, CA 92093 USA
[19] Duke Univ, Duke Clin Res Inst, Durham, NC USA
关键词
cost-effectiveness analysis; decision making; future directions; methods; policy; ECONOMICS APPROACH; STATE VALUATIONS; DECISION-MAKING; VALUE FRAMEWORK; 2ND PANEL; CARE; RECOMMENDATIONS; FAMILY; MODELS; GENERALIZABILITY;
D O I
10.1177/0272989X18798833
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives. In 2016, the Second Panel on Cost-effectiveness in Health and Medicine updated the seminal work of the original panel from 2 decades earlier. The Second Panel had an opportunity to reflect on the evolution of cost-effectiveness analysis (CEA) and to provide guidance for the next generation of practitioners and consumers. In this article, we present key topics for future research and policy. Methods. During the course of its deliberations, the Second Panel discussed numerous topics for advancing methods and for improving the use of CEA in decision making. We identify and consider 7 areas for which the panel believes that future research would be particularly fruitful. In each of these areas, we highlight outstanding research needs. The list is not intended as an exhaustive inventory but rather a set of key items that surfaced repeatedly in the panel's discussions. In the online Appendix, we also list and expound briefly on 8 other important topics. Results. We highlight 7 key areas: CEA and perspectives (determining, valuing, and summarizing elements for the analysis), modeling (comparative modeling and model transparency), health outcomes (valuing temporary health and path states, as well as health effects on caregivers), costing (a cost catalogue, valuing household production, and productivity effects), evidence synthesis (developing theory on learning across studies and combining data from clinical trials and observational studies), estimating and using cost-effectiveness thresholds (empirically representing 2 broad concepts: opportunity costs and public willingness to pay), and reporting and communicating CEAs (written protocols and a quality scoring system). Conclusions. Cost-effectiveness analysis remains a flourishing and evolving field with many opportunities for research. More work is needed on many fronts to understand how best to incorporate CEA into policy and practice.
引用
收藏
页码:767 / 777
页数:11
相关论文
共 50 条
  • [1] Standardizing cost-effectiveness analyses: The panel on cost-effectiveness in health and medicine
    Gold, MR
    [J]. ACADEMIC RADIOLOGY, 1998, 5 : S351 - S354
  • [2] Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions
    Cortesi, Paolo A.
    D'Angiolella, Lucia S.
    Lafranconi, Alessandra
    Micale, Mariangela
    Cesana, Giancarlo
    Mantovani, Lorenzo G.
    [J]. PHARMACOECONOMICS, 2018, 36 (03) : 263 - 284
  • [3] Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions
    Paolo A. Cortesi
    Lucia S. D’Angiolella
    Alessandra Lafranconi
    Mariangela Micale
    Giancarlo Cesana
    Lorenzo G. Mantovani
    [J]. PharmacoEconomics, 2018, 36 : 263 - 284
  • [4] COST-EFFECTIVENESS AND THE FUTURE OF MEDICINE
    SHULKIN, DJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 263 (01): : 40 - 40
  • [5] ANTICIPATED FUTURE DIRECTIONS IN COST-EFFECTIVENESS ANALYSIS
    BLUMSTEIN, A
    [J]. OPERATIONS RESEARCH, 1975, 23 : B263 - B263
  • [6] Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses Second Panel on Cost-Effectiveness in Health and Medicine
    Sanders, Gillian D.
    Neumann, Peter J.
    Basu, Anirban
    Brock, Dan W.
    Feeny, David
    Krahn, Murray
    Kuntz, Karen M.
    Meltzer, David O.
    Owens, Douglas K.
    Prosser, Lisa A.
    Salomon, Joshua A.
    Sculpher, Mark J.
    Trikalinos, Thomas A.
    Russell, Louise B.
    Siegel, Joanna E.
    Ganiats, Theodore G.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (10): : 1093 - 1103
  • [7] STANDARDS FOR COST-EFFECTIVENESS ANALYSES FOR THE FIELD OF HEALTH PSYCHOLOGY AND BEHAVIORAL MEDICINE
    Kaplan, Robert M.
    [J]. ANNALS OF BEHAVIORAL MEDICINE, 2018, 52 : S430 - S430
  • [8] Future drug prices and cost-effectiveness analyses
    Hoyle, Martin
    [J]. PHARMACOECONOMICS, 2008, 26 (07) : 589 - 602
  • [9] Future Drug Prices and Cost-Effectiveness Analyses
    Martin Hoyle
    [J]. PharmacoEconomics, 2008, 26 : 589 - 602
  • [10] Workshop on cost-effectiveness in health and medicine
    Glade, MJ
    [J]. NUTRITION, 1997, 13 (06) : 595 - 597